The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peng, Q.
Right arrow Articles by Zhou, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peng, Q.
Right arrow Articles by Zhou, W.
The Journal of Immunology, 2006, 176: 3330-3341.
Copyright © 2006 by The American Association of Immunologists

Dendritic Cell Synthesis of C3 Is Required for Full T Cell Activation and Development of a Th1 Phenotype1

Qi Peng, Ke Li, Hetal Patel, Steven H. Sacks and Wuding Zhou2

Department of Nephrology and Transplantation, King’s College London School of Medicine at Guy’s, King’s College and St. Thomas’ Hospitals, London, United Kingdom


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Previous studies have found that deficiency of complement component C3 is associated with reduced T cell responses in several disease models including viral infection, autoimmune disease, and transplantation. However, the underlying mechanism is unclear. In this study, we demonstrate that dendritic cells (DCs) are able to synthesize C3 and this synthesis is required for the capacity of DCs to stimulate alloreactive T cell responses in vitro and in vivo. Compared with C3-producing DCs, C3-nonproducing DCs exhibit reduced potency to stimulate an alloreactive T cell response, favor the polarization of CD4+ T cells toward Th2 phenotype, and have regulatory T cell-driving capacity. In addition, priming mice with C3-deficient DCs compared with wild-type DCs led to delayed skin allograft rejection. Our findings that nonproduction of C3 by DCs significantly reduced T cell stimulation and impaired allograft rejection provide a potentially important explanation of how C3-deficient mice develop reduced T cell responses and of how C3-deficient donor kidney is protected from T cell-mediated graft rejection.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Dendritic cells (DCs)3 and the complement system are two of the most important components of innate immunity, one being a cellular component and the other a humoral constituent (1, 2). In addition to participating in local inflammation and nonspecific immune responses, both DCs and complement have been shown to be important in regulating adaptive immune responses (3, 4). However, it is unclear whether these two components of innate immunity could cooperate in the regulation of the adaptive immune response.

DCs are the most potent APCs and are able to initiate an immune response by stimulating naive T cells. In addition, DCs have several other functions, such as the induction of tolerance, the regulation of T cell-mediated immunity by determining the balance between Th1 and Th2 responses and regulatory T cell development (5). It is becoming increasingly clear that the diverse functions of DCs are largely dependent on their state of activation, and this can be regulated by many mediators including exogenous and endogenous factors (6, 7, 8). These endogenous molecules have been proposed to play key roles in communicating an alarm signal to the immune system and promoting responses in transplants, tumors, infections, and autoimmunity (9).

The complement system is one of the earliest forms of host defense. It consists of a series of plasma components, receptors, and regulators, which react in a sequential manner. The functions of the complement system, such as microbial destruction, regulation of inflammatory responses, and disposal of waste, are achieved by complement effector products (e.g., C3b/C3d, C4b, C3a, and C5a) acting together with Ab and phagocytes, and through the formation of the complement membrane attack complex (2). In addition to the role in innate immunity, it has become increasingly evident that complement C3 participates in the regulation of Ag-specific immune responses. C3–/– mice exhibit an impaired B cell response to both T cell-dependent and -independent Ags (10, 11, 12). Direct attachment of C3d to hen egg lysozyme lowers the threshold for stimulating B cells by 1,000- to 10,000-fold (13). The mechanism of complement-mediated regulation of the B cell response appears to involve the interaction of complement-activation products (C3b, C3d) and complement receptors 1 and 2 (CR1/CD35, CR2/CD21) on cell surfaces, thus increasing the retention of Ag in lymphoid tissue and enhancing Ab production (4, 13). In addition to the regulation of B cell responses, participation of complement in T cell immunity has more recently been recognized. Impaired T cell responses in C3–/– mice were reported in several disease models including viral infection, autoimmune disease, and transplantation (14, 15, 16, 17). However, the means by which C3 deficiency leads to impaired Ag-specific T cell reactivity in such conditions remains unclear.

The liver is the primary site for the synthesis of C3 (18); however, many other specialized cells have the capacity to synthesize C3 including myeloid-derived cells and parenchymal cells (19, 20, 21, 22). These cells synthesize C3 spontaneously or in response to stimulation by cytokines or microbial factors. The importance of local synthesis of C3 has been demonstrated in bacterial infection and kidney transplant models in vivo. When C3-deficient mice were reconstituted with wild-type (WT) bone morrow cells, local synthesis of C3 in the spleen and lymph nodes and the ability to make an Ab response to exogenous Ags were restored (23). C3-deficient mouse kidney, when transplanted into allogeneic WT mice, survived for at least 100 days (vs 14 days for C3-sufficient mouse kidney) (24). Although the underlying mechanism is unclear, this observation suggests that local (intrarenal) synthesis of C3 is as an important determinant of the alloimmune response and that C3-producing cells identifiable in the donor kidney may contribute to T cell-mediated graft rejection. Because donor-derived DCs are an important constituent of solid organ transplants and play a crucial role in the initiation and maintenance of the T cell alloresponse (25, 26), this raises the possibility that local synthesis of C3 by DCs is needed for T cell activation.

However, to date, it is unclear whether DCs, the most potent APCs, are able to synthesize C3. Given the importance of C3 for both the pathological and physiological regulation of nonspecific and specific immune responses, DC synthesis of C3 could be an important contributory factor in DC activation and their other diverse functions.

In this study, we explored the hypothesis that DCs are able to synthesize C3 and this synthesis can modulate DC functions, therefore contributing to T cell responses. We examined C3 synthesis in murine bone marrow-derived DCs by RT-PCR, ELISA, and immunochemical staining. Using a mouse model of T cell alloreactivity, with either C3–/– or C3+/+ mice as the stimulator strain, we studied the effect of DC synthesis of C3 on DC functions in alloreactive T cell responses, including T cell stimulation, T cell polarization, regulatory T cell development, and skin allograft rejection.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Mice

Homozygous C3–/– mice were generated by Prof. M. Carroll and colleagues (11) using homologous recombination in embryonic stem cells. These mice were then backcrossed in our laboratory onto the C57BL/6 parental strain for 11 generations. Skin grafts between the backcrossed C3–/– and congenic strains showed long-term graft survival (>100 days). C3+/+ mice (C57BL/6), BALB/c, and B10Br were purchased from Harlan. Male mice (6–7 wk old) were used in all experiments. All animal procedures were conducted within the Animals Act U.K. (Scientific Procedures, 1986).

DC cultures

DCs were cultured from bone marrow progenitor cells using a modified protocol of a previously described method (27). In brief, bone marrow cells were harvested from mouse femurs and tibias. Usually, bone marrow cells were harvested from three to four mice. Washed bone marrow cells were prepared in DC culture medium (RPMI 1640 medium, 5% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µM 2-ME, 20 ng/ml GM-CSF), at a density of 1 x 106 cells/ml, then plated in 24-well plates at 1 ml/well. Culture medium was replaced with fresh medium every 2 days. At day 6, dislodged cells were collected and purified with CD11c MicroBeads (Miltenyi Biotec). Purified cells were cultured for an additional 2 days in addition of LPS (1 µg/ml) to allow the cells to mature, unless otherwise specified.

Preparation of peritoneal macrophages

Peritoneal macrophages were prepared from mice inoculated i.p. with 1 ml of 3% thioglycolate. After 6 days, the peritoneal cell population was harvested and purified with CD11b MicroBeads (Miltenyi Biotec).

Immunochemical staining

DCs cultured for 8 days on coverslips were fixed with paraformaldehyde, and then stained for C3 using an indirect method. The Abs used were: goat anti-mouse C3 (ICN Pharmaceuticals) and FITC-conjugated donkey anti-goat IgG (Jackson ImmunoResearch Laboratories).

Flow cytometry

For analysis of surface molecule expression, 2 x 105 DCs or T cells were stained with FITC or PE-conjugated Ab or the appropriate isotype control Ab, at 4°C for 30 min followed by washing three times in 2 ml of PBS with 1% BSA. The cells were then fixed in 400 µl of 1% paraformaldehyde in PBS. For analysis of foxp3 expression, cells were first stained for the expression of surface molecule (CD4) and, after fixation and permeabilization, were incubated with PE-conjugated Ab based on the manufacturer’s recommendation. The stained cells were analyzed by flow cytometry (FACScan; BD Biosciences). Ab reagents used in flow cytometry are as follows. FITC-conjugated mouse anti-mouse MHC class I (H-2Db, CTDb; Serotec); PE-conjugated rat anti-mouse MHC class II (I-A/I-E, M5/114.15.2), PE-conjugated rat anti-mouse CD40 (3/23), PE-conjugated Armenian hamster anti-mouse ICAM-1 (CD54, 3E2), and PE-conjugated rat anti-mouse B7.2 (CD86, GL1; BD Biosciences). PE-conjugated rat anti-mouse Foxp3 and PE-conjugated rat anti-mouse F4/80 (eBioscience).

ELISA

Sandwich ELISA was performed using OptEIA ELISA set for mouse IL-2, IFN-{gamma}, IL-4, IL-10, and IL-12 (BD Biosciences) according to the manufacturer’s instructions. Mouse C3 ELISA was performed using sheep anti-mouse C3 (ICN Biomedicals) and HRP-conjugated goat anti-mouse C3 (Nordic). The standard used here was pooled normal mouse serum, which has a reported C3 concentration of 0.7 mg/ml (28).

Conventional RT-PCR

Total RNA was extracted from the cell pellets and subsequently used for semiquantitative PCR. PCR was conducted with 2 µl of diluted cDNA (reflecting 0.2 µg of total RNA), 12.5 pmol of each 3' and 5' primer pair, either for each testing gene or GAPDH gene (Table I), in 25 µl of reaction buffer (Promega). The PCR cycle consisted of 1 min at 94°C, 1 min at 62°C, and 1 min at 72°C. Amplified PCR products were visualized after electrophoresis on 1.5 or 2% agarose gel containing ethidium bromide. GAPDH primers, 12.5 pmol each, were added in every reaction as an internal control.


View this table:
[in this window]
[in a new window]
 
Table I. PCR primer sequences and product sizes

 
RT-quantitative PCR (RT-qPCR)

Real-time RT-qPCR was performed with an MJ Research PTC-200 Peltier Thermal Cycler and DyNAmo HS SYBR Green qPCR kit (MJ BioWorks). PCR was setup in low-profile microplates containing 10 µl of master mix, 2 µl of diluted cDNA (reflecting 0.2 µg of total RNA), 10 pmol of each 3' and 5' primer pair, either for each testing gene or GAPDH gene (Table I), in a 20-µl reaction volume. Amplification was performed according to manufacturer’s cycling protocol and done in triplicate. Gene expression was expressed as 2{Delta}{Delta}(Ct) (29), where Ct is cycle threshold, {Delta}{Delta}(Ct) = sample 1{Delta}(Ct) – sample 2{Delta}(Ct); {Delta}(Ct) = GAPDH (Ct) – testing gene (Ct).

Preparation of T cells

Naive alloreactive T cells were derived from spleens of normal BALB/c mice. Usually, splenocytes from four to five mice were used for the T cell preparation. CD3+, CD4+, and CD8+ T cells were prepared from splenocytes using the Spin-Sep Enrichment Cocktail kit (StemCell Technologies). Following the preparation, the purity of the T cell preparation was routinely >90%, as determined by flow cytometry.

Analysis of alloreactive T cell response in vitro

A total of 5 x 104 irradiated (2000 rad) DCs and 2 x 105 purified alloreactive T cells (CD3+ or CD4+ or CD8+) were cocultured in T cell culture medium (RPMI 1640 containing 10% heat-inactivated FCS, 50 µM 2-ME, 100 U/ml penicillin, and 100 µg/ml streptomycin) for up to 11 days, unless otherwise specified. Culture supernatants were analyzed for IFN-{gamma}, IL-2, IL-4, and IL-10 using ELISA.

Analysis of immune response in vivo

BALB/cH-2d or B10BrH-2k mice, at day 0, were given 5 x 105 irradiated (2000 rad) donor DCs (C57BL/6H-2b, ether C3+/+ or C3–/–). Fourteen days after administration, mice were killed. The spleen was used for the assessment of T cell response ex vivo by MLR.

Mixed lymphocyte reaction

Splenocytes (2 x 105) derived from immunized BALB/cH-2d mice or B10BrH-2k mice and irradiated (2000 rad) splenocytes (2 x 105) derived from C57BL/6H-2b were cocultured in T cell culture medium for up to 9 days. For measuring the production of IFN-{gamma}, IL-2, and IL-10 by T cells, coculture supernatants were collected at various time points and used to perform ELISA. T cell proliferation was assessed at 96 h after coculture by measuring the incorporation of [3H]thymidine.

[3H]Thymidine incorporation assay

[3H]Thymidine (1 µCi/well) was added in the cocultures during the last 16 h according to the manufacturer’s instruction. The amount of [3H]thymidine incorporation was counted. Control cultures included wells of irradiated stimulator with irradiated T cells. Data were expressed as the difference in cpm of experimental and control cultures. T cells alone and stimulator (DCs or donor splenocytes) alone controls were also included in each experiment and gave consistently low backgrounds.

Generation of CD4+CD25+ T cells in vitro and T cell suppression assay

To generate CD4+CD25+ T regulatory cells, we used a previously described method with modifications (30). In brief, naive CD4+ T cells (H-2d) were cocultured with irradiated allogeneic C3+/+ or C3–/– DCs (H-2b), at a ratio of 4:1. After coculturing for 9 days, T cells were harvested and cocultured with fresh irradiated C3+/+ or C3–/– DCs for a further 9 days in the conditioned medium (containing 50% of previous supernatant and 50% fresh medium). After coculturing for 18 days, the percentage of CD4+CD25+ T cells in our preparations was 30–35% as determined by flow cytometry. The enriched CD4+CD25+ T cell preparations were subsequently used for T cell suppression assays.

Skin grafting

Tail skin from donor animals was grafted onto the left flank of recipients under isoflurane anesthetic. The graft site was covered with paraffin-embedded gauze, a dressing of dry gauze and secured with Transpore 3M adhesive tape. The dressing was removed on day 5, and the grafts were assessed visually on a daily basis for signs of rejection. The time to rejection was determined as the day on which >80% of the graft area was necrotic. The groups were assessed in a blinded fashion.

C3 gene silencing

C3+/+ DCs (5 x 105) were transfected with a range of C3 small interfering RNA (siRNA) concentrations (sense sequence: 5'-GGAAUUCAACUCA GAUAAGtt-3'; antisense sequence: 5'-CUUAUCUGAGUUGAAUUC Ctt-3') or silencer negative control siRNAs (Ambion) using siRNA transfection kit (Qiagen). Forty-eight hours after transfection, culture supernatants were analyzed for C3 by ELISA; DCs were irradiated (2000 rad) and used for T cell stimulation. DCs (5 x 104) were cocultured with naive alloreactive CD4+ T cells (2 x 105) for 3 days. Culture supernatants were then analyzed for IFN-{gamma} using ELISA.

Statistical analysis

ELISA or T cell proliferation assays were performed in three to six replicate wells of the cocultures. Results were expressed as a mean ± SEM and subjected to statistical analysis. Student’s t test or two-way ANOVA or one-way ANOVA was used where appropriate to determine significant differences between samples. The graft survival data were analyzed using the Mantel-Haenszel test. All experiments were repeated at least three times.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Synthesis of C3 by DCs

Bone morrow-derived cells from WT mice were cultured in DC culture medium for 6 days. Purified DCs were cultured for an additional 2 days in the presence of LPS. After culturing for 8 days, the majority of cells expressed high levels of MHC class I, MHC class II, and costimulatory molecules CD40, ICAM-1, B7.1, and B7.2. Staining of all DC preparations was negative for the macrophage marker F4/80, suggesting that contamination with macrophages was minimal (data not shown).

To investigate whether these WT DCs have the ability to synthesize C3, we performed RT-PCR, ELISA, and immunochemical staining. Using RT-PCR, we detected mRNA transcript for C3 (282 bp), which had identical electrophoretic mobility to that from macrophages (positive control), but which was not detected in DCs derived from C3–/– mice (Fig. 1A).


Figure 1
View larger version (23K):
[in this window]
[in a new window]
 
FIGURE 1. Synthesis of C3 by DCs. A, RT-PCR. Total RNA was extracted from the cell pellets of WT or C3–/– DCs as well as of macrophages (M{phi}), and subsequently used for semiquantitative PCR. An agarose gel showing the 282-bp C3 band and the 453-bp GAPDH (internal control) band. B, ELISA. Culture supernatants of WT DCs or C3–/– DCs that were further cultured for 3 days in the presence of LPS in culture medium, after purification at day 6, were analyzed for C3 using ELISA. M{phi} culture supernatants were used in control studies. C, ELISA. Culture supernatants of C3+/+ DCs that were further cultured for up to 7 days either in the presence or absence of LPS in culture medium, after purification at day 6, were analyzed for C3 by ELISA. D, Immunochemical staining. C3 staining was performed on DCs derived from WT and C3–/– mice and cultured for 8 days. Data were analyzed by two-way ANOVA. Values of p are for comparisons between LPS-treated and untreated C3+/+ DCs. All results are representative of at least three independent experiments.

 
To detect C3 protein secreted by DCs, we cultured DCs from WT mice and purified them at day 6 with CD11c beads. A total of 2 x 105 purified cells were then further cultured for 3 days in 0.2 ml of DC culture medium, in the presence of LPS. Culture supernatants were analyzed for C3 using ELISA. We also collected supernatants from peritoneal macrophages (2 x 105) cultured for 3 days for the positive control and supernatants from C3–/– DC cultures for the negative control. As shown in Fig. 1B, C3 was detected in the supernatants of WT DC and macrophage cultures (at 192 ± 1.8 and 113 ± 9.6 ng/ml, respectively), but not detected in the supernatants of C3–/– DC cultures. To examine the effect of LPS on DC synthesis of C3, we cultured DCs from WT mice and purified them at day 6 with CD11c beads. A total of 2 x 105 purified cells were then further cultured for up to 7 days, either in the presence or absence of LPS. Culture supernatants were analyzed for C3 using ELISA. We found that DCs were able to produce C3 in the absence of LPS; however, the production was significantly increased in the presence of LPS (Fig. 1C).

We also performed cellular immunochemical staining for C3 on WT DCs cultured for 8 days. DCs were uniformly stained with an anti-mouse C3 Ab, but staining was negative on DCs derived from C3–/– mice (Fig. 1D). Thus, cultured BM DCs have the ability to synthesize and secrete C3, and this synthesis is up-regulated by LPS.

C3–/– DCs have reduced potency to stimulate alloreactive CD4+ T cells in vitro

We next tested the hypothesis that local synthesis of C3 by DCs influences the potency of DCs to stimulate alloreactive T cells. For this purpose, we used responder T cells, including CD4+, CD3+, and CD8+ T cells, prepared from the spleens of naive BALB/cH-2d mice, and stimulator DCs prepared from allogeneic C57BL/6H-2b mice (either C3+/+ or C3–/–). Purified CD4 T cells were also prepared from C57BL/6 H-2b as syngeneic controls. The T cells were cocultured with irradiated DCs for up to 7 days. T cell activation was then assessed by measuring the level of IFN-{gamma} and IL-2 in the culture supernatant using ELISA. We found that the production of IFN-{gamma} and IL-2 was significantly lower in alloreactive CD4+ T cells stimulated by C3–/– DCs compared with those stimulated by C3+/+ DCs. The effect of the C3 status of DCs on the T cell response was more pronounced in CD4+ T cells and undetectable in CD8+ T cells (Fig. 2). Thus, deficient production of C3 by DCs rendered them less potent to stimulate alloreactive CD4 T cells but not CD8 T cells. These data suggest that the effect of C3 was primarily on the MHC class II-dependent pathway of donor Ag presentation. Syngeneic controls exhibited only a very low level of cytokine production (data not shown), showing the observed T cell response was specific for donor Ag.


Figure 2
View larger version (24K):
[in this window]
[in a new window]
 
FIGURE 2. C3–/– DCs have reduced potency to stimulate alloreactive CD4+ T cells in vitro. Irradiated DCs (5 x 104) from either C3+/+ or C3–/– C57BL/6 mice were cocultured, respectively, with naive alloreactive CD3+, CD4+, and CD8+ T cells (2 x 105) from BALB/c mice for up to 7 days. Culture supernatants were then analyzed for IFN-{gamma} (A) and IL-2 (B) by ELISA. Data were analyzed by two-way ANOVA. Values of p are for comparisons between C3+/+ and C3–/– DCs. Results are representative of four independent experiments.

 
Reduced capacity of C3–/– DCs for immune stimulation in vivo

Next, we determined whether C3–/– DCs have a reduced ability to elicit an alloreactive T cell response in vivo. At day 0, BALB/cH-2d or B10BrH-2k mice were given 5 x 105 donor DCs (either C3+/+ or C3–/–) by i.p. injection. On day 14, mice were killed and their splenocytes were used for analysis of the alloreactive T cell response ex vivo using MLR, where splenocytes derived from the above DC administered BALB/c or B10Br mice were used as the responders, and in which allogeneic splenocytes from C57BL/6 mice were used as stimulators. T cell activation was assessed by measuring IFN-{gamma} and IL-2 in the culture supernatant using ELISA. The T cell response in mice (both BALB/c and B10Br) that had received C3–/– DCs was impaired, with significant lowering of IFN-{gamma} and IL-2 production, compared with mice that had received C3+/+ DCs (Fig. 3). Thus, administration of C3–/– DCs resulted in defective T cell activation. Both BALB/c and B10Br mice received C3–/– DCs developed weaker T cell activation, suggesting that the effect of complement was allo- but not strain-dependent.


Figure 3
View larger version (19K):
[in this window]
[in a new window]
 
FIGURE 3. Reduced capacity of C3–/– DCs for immune stimulation in vivo. BALB/c mice (n = 2) or B10Br (n = 2) mice were administered with irradiated donor DCs (5 x 105) either from C3+/+ or C3–/– mice for 14 days. T cell response in those mice was assessed by restimulation ex vivo (MLR). Allogeneic splenocytes (2 x 105) derived from C57BL/6 mice were cocultured with splenocytes (2 x 105) derived from the DC administered BALB/c or B10Br mice for up to 9 days. Culture supernatants were analyzed for IFN-{gamma} (A) and IL-2 (B) by ELISA. Data were analyzed by two-way ANOVA. Values of p are for comparisons between C3+/+ and C3–/– DCs. Results are representative of three independent experiments.

 
C3–/– DCs favor the polarization of CD4+ T cells toward Th2 phenotype

Because DCs are not only able to initiate activation of naive T cells, but also play an important role in determining the direction of the immune response, we asked whether DC synthesis of C3 could also have an effect on its T cell-polarizing capacity. To test the hypothesis, we cocultured irradiated C3+/+ or C3–/– DCs with purified naive alloreactive CD4+ T cells for up to 11 days. Then, we measured the production of IFN-{gamma} and IL-4 in the culture supernatants using ELISA. The production of IFN-{gamma} (Th1 cytokine) in T cells stimulated by C3–/– DCs was consistently lower than that stimulated by C3+/+ DCs (from days 5 to 11 of coculture) (Fig. 4A). In contrast, the production of IL-4 (Th2 cytokine) in T cells stimulated by C3–/– DCs was higher than that stimulated by C3+/+ DCs, at 7–11 days of coculture (Fig. 4B). Thus, C3+/+ DCs and C3–/– DCs exhibited different T cell-polarizing capacity, where C3+/+ DCs favor the polarization of CD4+ T cells toward a Th1 phenotype, and C3–/– DCs favor the polarization of CD4+ T cells toward a Th2 phenotype.


Figure 4
View larger version (16K):
[in this window]
[in a new window]
 
FIGURE 4. C3–/– DCs favor the polarization of CD4+ T cells toward Th2 phenotype. A and B, Irradiated DCs (5 x 104) from either C3+/+ or C3–/– C57BL/6 mice were cocultured with naive alloreactive CD4+ T cells (2 x 105) from BALB/c mice for up to 11 days. Culture supernatants were then analyzed for IFN-{gamma} (A) and IL-4 (B) by ELISA. C, Nonirradiated DCs (2 x 105) from WT or C3–/– mice, after purification at day 6, were further cultured for 24 or 48 h in 0.2 ml of medium in the presence of LPS. Culture supernatants were then analyzed for IL-12 by ELISA. Data were analyzed by two-way ANOVA. Values of p are for comparisons between C3+/+ and C3–/– DCs. Results are representative of three independent experiments.

 
A unique function for DCs is to express a selective set of T cell-polarizing molecules that determine the balance between Th1 and Th2 development. Therefore, we sought to determine whether there is differential expression of Th1-polarizing cytokine (IL-12) in C3+/+ and C3–/– DCs. We cultured DCs from WT or C3–/– mice, and after purification at day 6 with CD11c beads, cultured them for an additional 2 days in the presence of LPS. Culture supernatants were analyzed for IL-12 using ELISA. We found that the production of IL-12 was significantly lower in C3–/– DC cultures compared with C3+/+ DC cultures (Fig. 4C).

C3–/– DCs have regulatory T cell driving capacity

As IL-10 has been implicated as a (co-) factor responsible for the induction of regulatory T cell development (31, 32), we studied whether the C3 status of DCs would have an effect on IL-10 production by CD4+ T cells. We cocultured irradiated C3+/+ or C3–/– DCs with purified naive alloreactive CD4+ T cells for up to 11 days. Culture supernatants were analyzed for IL-10 using ELISA. We found that the production of IL-10 was significantly higher in T cells stimulated by C3–/– DCs than that stimulated by C3+/+ DCs, at 7–11 days of coculture (Fig. 5A).


Figure 5
View larger version (21K):
[in this window]
[in a new window]
 
FIGURE 5. C3–/– DCs have regulatory T cell driving capacity. Irradiated DCs (5 x 104) from either C3+/+ or C3–/– C57BL/6 mice were cocultured with naive alloreactive CD4+ T cells (2 x 105) from BALB/c mice for up to 11 days. A, Culture supernatants were then analyzed for IL-10 by ELISA. Data were analyzed by two-way ANOVA. Results are representative of three independent experiments. B and C, Cell pellets from the coculture at day 9 were analyzed for foxp3 expression by RT-PCR. B, A typical agarose gel showing the 118-bp foxp3 band and the 453-bp GAPDH (internal control) band. The 100-bp DNA markers (M) are shown along side the gel. C, The results of RT-qPCR. Data were from triplicate PCR that were performed on cDNAs derived from two independent cocultures and analyzed by Student’s t test. **, p < 0.01; ***, p < 0.001. Values of p are for comparisons between C3+/+ and C3–/– DCs. D, In another set of experiments, CD4+ T cells were cocultured with C3+/+ or C3–/– DCs for 9 and 18 days. Intracellular foxp3 expression in these CD4+ T cells was assessed using flow cytometry. Results are representative of three independent cocultures.

 
Increasing evidence indicates that DCs are able to expand Ag-specific CD4+CD25+ regulatory T cells (32, 33). Therefore, we asked whether C3+/+ and C3–/– DCs have different abilities to elicit the development of regulatory T cells. Regulatory T cells specifically express forkhead transcription factor gene (foxp3), which is thought to be a marker for CD4+CD25+ regulatory T cells (34). We cocultured CD4+ T cells with allogeneic C3+/+ or C3–/– DCs for 9 days and then performed conventional RT-PCR and RT-qPCR for the detection of foxp3 gene expression in stimulated T cells. We detected mRNA transcript for foxp3 (118 bp) in both groups of stimulated T cells (Fig. 5B). However, the level was increased ~4-fold in T cells stimulated by C3–/– DCs compared with those stimulated by C3+/+ DCs (Fig. 5C). In another set of experiments, we cocultured CD4+ T cells with allogeneic C3+/+ or C3–/– DCs for 9 and 18 days, then examined intracellular foxp3 protein expression in these CD4+ T cells using flow cytometry. We found the percentage of foxp3+ T cells was about 2-fold higher in CD4+ T cells stimulated by C3–/– DCs than in that stimulated by C3+/+ DCs (Fig. 5D). Thus, CD4+ T cells primed by C3–/– DCs in vitro showed elevation of IL-10 production and foxp3 expression, suggesting that the generation of regulatory T cells was dependent on C3.

Suppression of the alloreactive T cell response by C3–/– DC-stimulated CD4+ T cells

To further investigate whether C3–/– DC-stimulated CD4+ T cells could have regulatory T cell function, thus modulating the alloreactive T cell response, we performed a T cell suppression assay. Enriched CD4+CD25+ T cells were prepared in vitro by coculturing CD4+ T cells with allogeneic DCs (either C3+/+ or C3–/–) for 18 days as described in Materials and Methods. The T cell suppression assay was setup by adding enriched CD4+CD25+ T cells to a coculture of CD4+ T cells (H-2d) and irradiated C3+/+ DCs (H-2b), at a ratio of 1:1:4 for enriched CD4+CD25+ T cells, DCs, and CD4+ T cells. Inhibition of the T cell response was assessed at 4 days after coculture by cytokine measurement and incorporation of [3H]thymidine. Results showed that enriched CD4+CD25+ T cell preparation generated by C3–/– DC stimulation significantly inhibited T cell activation and T cell proliferation, but this effect was less pronounced when using enriched CD4+CD25+ T cells generated by C3+/+ DC stimulation (Fig. 6).


Figure 6
View larger version (22K):
[in this window]
[in a new window]
 
FIGURE 6. Suppression of the alloreactive T cell response by C3–/– DC-stimulated CD4+ T cells. Enriched CD4+CD25+ T cells were prepared in vitro by coculturing CD4+ T cells with allogeneic DCs (either C3+/+ or C3–/–) for 18 days as described in Materials and Methods. T cell suppression assays were set up by adding in enriched CD4+CD25+ T cells in a coculture of CD4+ T cells (H-2d) and irradiated C3+/+ DCs (H-2b), at a ratio of 1:1:4 for enriched CD4+CD25+ T cells, DCs, and CD4+ T cells. The inhibition of T cell response was assessed at 4 days after culture by cytokine measurement (A) and incorporation of [3H]thymidine (B). Data were from three cocultures and analyzed by Student’s t test. **, p < 0.01; ***, p < 0.001. Values of p are for comparisons between C3+/+ and C3–/– DC stimulations.

 
C3–/– DCs elicited delayed skin allograft rejection

As demonstrated above, C3–/– DCs have an impaired potency to stimulate an alloreactive T cell response, favor the polarization of CD4-positive T cells toward Th2 phenotype and have regulatory T cell-driving capacity. This suggests that C3–/– DCs can down-regulate the alloimmune response. Next, we investigated whether the immunization of recipient mice with donor C3–/– DCs could delay allograft rejection in a murine skin transplant model, compared with the use of WT DCs. Bone marrow-derived immature DCs were prepared from either C3+/+ or C3–/– mice (H-2b) and irradiated. B10Br mice (H-2k) (n = 15/group), at day 0, were given either C3+/+ or C3–/– DCs (H-2b) by i.p. injection; 14 days after the administration of DCs the mice received a C57BL/6 (H-2b) skin graft (derived from C3–/– mice). Skin grafts (n = 11/group) were monitored day 5 onwards after skin transplantation. T cell responses in the remaining B10Br mice (n = 4/group) were measured ex vivo by MLR at day 7 after skin grafting. Our results showed that mice immunized with C3–/– DCs had significantly delayed graft rejection and had lowered T cell responses ex vivo (with reduced [3H]thymidine uptake and lower level of IFN-{gamma} and higher level of IL-10 production) compared with mice that had received C3+/+ DCs (Fig. 7). Although the difference in graft survival between mice administered with C3+/+ and C3–/– DCs is relatively small, we used a fully MHC-mismatched strain combination in which the window for skin graft rejection is small, usually within 7 days (35). Given this stringency, prolongation of skin graft survival even by 2 or 3 days is significant and can reflect a reduced T cell response in the host. In support, we demonstrated a clear difference in alloreactive T cell responses between mice primed with C3+/+ and C3–/– DCs. Taking together the skin graft survival studies and T cell response data, our results indicate that defective T cell priming with C3–/– DCs can result in delayed allograft rejection.


Figure 7
View larger version (15K):
[in this window]
[in a new window]
 
FIGURE 7. C3–/– DCs elicited delayed skin allograft rejection. B10Br mice (H-2k) (15/group), at day 0, were given either PBS or C3+/+ or C3–/– DCs (H-2b) (5 x 106, irradiated at 2000 rad) by i.p. injection; 14 days after the administration of DCs the mice received a C57BL/6 (H-2b) skin graft (derived from C3–/– mice). A, Skin grafts (n = 11/group) were monitored day 5 onwards after skin transplantation. Data for skin graft rejection were analyzed by Mantel-Haenszel test. B–D, T cell responses in the remaining B10Br mice (n = 4/group) were measured ex vivo by MLR at day 7 after skin grafting. T cell proliferation was assessed by [3H]thymidine incorporation (B), and the secretion of IFN-{gamma} (C), and IL-10 (D) in culture supernatants was assessed by ELISA. Data were analyzed by Student’s t test. *, p < 0.05; **, p < 0.01; ***, p < 0.001. Values of p are for comparisons between C3+/+ and C3–/– DCs.

 
C3 gene-silenced DCs have lowered ability to stimulate alloreactive T cells

To verify the importance of C3 on the T cell stimulatory ability of DCs, we performed inhibitory studies using WT DC. We inhibited C3 gene expression in C3+/+ DCs using siRNA, and measured the ability of these DCs to stimulate alloreactive T cells compared with control-treated DCs. As shown in Fig. 8, treatment with C3 siRNA, at the concentrations of 50 or 100 nM, significantly reduced the amount of C3 secreted, and co-coordinately lowered the level of T cell activation elicited by these DCs. However, treatment with irrelevant siRNA at the concentration of 100 nM did not significantly reduce the amount of C3 produced or lower the level of T cell activation. These data provide evidence that endogenous production of C3 by DCs is required for DCs to function as potent APCs. Our data also suggest that the reduced potency of C3–/– DCs to stimulate alloreactive T cells is not due to an artifact of the homologous recombination procedure.


Figure 8
View larger version (24K):
[in this window]
[in a new window]
 
FIGURE 8. C3 gene-silenced DCs have lowered ability to stimulate alloreactive T cells. C3+/+ DCs were transfected with a range of C3 siRNA concentrations or control siRNA using a transfection kit (Qiagen) for 48 h. A, Supernatants of the treated DCs were analyzed for C3 by ELISA. B, The treated DCs (5 x 104) were then cocultured with 2 x 105 naive alloreactive CD4+ T cells for 3 days. Culture supernatants were analyzed for IFN-{gamma} by ELISA. Data were analyzed by one-way ANOVA. Values of p are for comparisons between control siRNA treated and C3 siRNA treated DCs. Results are representative of three independent experiments.

 
C3–/– DCs have no intrinsic gene defect for MHC class II and costimulatory molecules

There is a possibility that the recombinant DNA procedure used to generate the C3–/– mice interfered with nontargeted genes that are critical for immune stimulation. To investigate this prospect, we examined the gene expression of MHC class II, CD40, ICAM-1, and B7.2. DCs were cultured for 7 days without LPS stimulation or for 8 days where LPS was present on the final 2 days of culture. Using conventional RT-PCR and RT-qPCR, we found that all of these genes were transcribed in both C3+/+ and C3–/– DCs (Fig. 9A). The level of gene expression in C3–/– DCs showed no defect when compared with that of C3+/+ DCs in both 7- and 8-day cultures. In fact, the level of gene expression of MHC class II, CD40, and ICAM-1 was slightly elevated in C3–/– DCs of 8-day cultures (Fig. 9, B and C). This data is consistent with our observations in C3–/– macrophages (data not shown). The reason for this elevation is not clear, but perhaps reflects a compensatory response to defective Ag presentation.


Figure 9
View larger version (21K):
[in this window]
[in a new window]
 
FIGURE 9. C3–/– DCs have no intrinsic gene defect for MHC class II, CD40, ICAM-1, and B7.2 molecules, but reduced cell surface expression of MHC class II and B7.2 in maturing DCs. A and B, WT or C3–/– DCs cultured for 7 days without LPS stimulation were used for RT-PCR. A, A typical agarose gel showing PCR products for MHC class II, CD40, ICAM-1, B7.2, and GAPDH. The 100-bp DNA markers (M) are shown along side the gel. B, The results of RT-qPCR. Data were analyzed by Student’s t test. Values of p are for comparisons between C3+/+ and C3–/– DCs; p value: NS. C and D, WT or C3–/– DCs from three mice were cultured for 8 days, with LPS stimulation at the last 48 h. Cells were used for RT-PCR and flow cytometry analysis of surface expression of MHC class II, CD40, ICAM-1, B7.1, and B7.2. C, The results of RT-qPCR. D, The results of flow cytometry. Data were expressed as mean fluorescence intensities (MFI). All results are representative of three independent experiments.

 
Reduced cell surface expression of MHC class II and B7.2 in C3–/– DCs

Next, we examined the protein expression for MHC class II and costimulatory molecules to determine whether there had been altered cell surface expression of these important immune regulators in C3–/– DCs. The results of flow cytometric analysis of cell surface MHC class II, CD40, ICAM-1, and B7.2 expression in LPS-stimulated DCs are presented in Fig. 9D. We found that the level of surface expression of MHC class II and B7.2 was consistently lower (21–25% and 21–30%, respectively) in C3–/– DCs than in C3+/+ DCs. Although this reduction is relatively small, this observation was made in three independent experiments, where DCs were prepared from three mice in each case. In addition, we obtained similar results on macrophages and lymphocytes derived from C3–/– mice (data not shown). Given that surface expression of MHC molecules is a key determinant for the ability of APCs to stimulate T cells, and B7.2 is a critical factor for the amplification of T cell responses, the reduced surface expression of MHC class II and B7.2 molecules on C3–/– DCs could contribute to their weaker effect in allostimulation.

C3–/– DCs have no hyporesponsiveness to LPS stimulation

LPS treatment of BM-derived DCs can increase the proportion of mature cells and therefore enhance the capacity of DCs for T cell stimulation. As C3–/– DCs have reduced ability to stimulate alloreactive CD4+ T cells, we sought to determine whether C3–/– DCs also exhibit hyporesponsiveness to TLR4 ligand (LPS) stimulation. We assessed the gene expression and functional activity of TLR4 in C3+/+ and C3–/– DCs following LPS stimulation. Using conventional RT-PCR and RT-qPCR, we found that C3–/– DCs have no gene expression defect for TLR4. Surprisingly, the level of TLR4 mRNA in C3–/– DCs was elevated compared with C3+/+ DCs. The production of TNF-{alpha} by C3–/– DCs was comparable to that with C3+/+ DCs, in the presence or absence of LPS in the DC culture medium (Fig. 10). Therefore, C3–/– DCs have no hyporesponsiveness to LPS stimulation.


Figure 10
View larger version (24K):
[in this window]
[in a new window]
 
FIGURE 10. C3–/– DCs have no hyporesponsiveness to LPS stimulation. A and B, WT and C3–/– DCs were cultured for 8 days were used for RNA extraction and cDNA synthesis, and subsequently for RT-PCR. A, A typical agarose gel showing the 326-bp TLR4 band and the 453-bp GAPDH (internal control) band. The 100-bp DNA markers (M) are shown along side the gel. B, The results of RT-qPCR. C, Nonirradiated DCs (2 x 105) from WT or C3–/– mice, after purification at day 6, were further cultured in 0.2 ml of medium for 48 h, in the presence or absence of LPS. Supernatants of DC culture were then analyzed for TNF-{alpha} by ELISA. Data in B and C were analyzed by Student’s t test. **, p < 0.001. Values of p are for comparisons between C3+/+ and C3–/– DCs. All results are representative of three independent experiments.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Identifying specific stimulatory pathways and molecules that determine the diverse functions of DCs is critical for understanding and manipulating adaptive immunity. Although it is becoming clear that microbial and viral components acting on TLRs lead to DC activation, endogenous and physiologic molecules that could modulate the activation states of DCs remain mostly unidentified. The work presented here shows that murine BM-derived DCs are able to synthesize C3 and this synthesis is required for DCs to develop a fully activated phenotype capable of eliciting a Th1 response.

Our data show that DCs cultured from WT mice are capable of synthesizing a substantial amount of C3 and this synthesis is up-regulated by LPS stimulation. The quantity of C3 released by DCs are comparable to that produced by macrophages, which are considered to be an important extrahepatic source of C3 (19). Our study therefore identifies a novel property of BM-derived DCs, namely the ability to synthesize and secrete C3. In addition, our findings offer insight into the regulation of the T cell response by local production of C3.

To investigate the functional relevance of DC synthesis of C3 in the adaptive T cell response, we used a transplant model, where alloantigen was synthesized and presented by donor DCs to alloreactive T cells. DCs cultured from C3+/+ and C3–/– mice exhibited different properties, in terms of stimulating and regulating specific T cell responses. Compared with C3+/+ DCs, C3–/– DCs displayed reduced surface expression of MHC class II and B7.2 on the cell surface, and showed reduced production of the Th1-polarizing molecule, IL-12, which is a potent inducer of IFN-{gamma} production leading to the development of Th1 responses. Furthermore, C3–/– DCs elicited significantly lower alloreactive T cell responses in vitro and in vivo. In contrast to C3+/+ DCs, C3–/– DCs induced naive CD4+ T cells to produce a higher level of Th2 cytokine (IL-4) and a lower level of Th1 cytokine (IFN-{gamma}). These data suggest that DCs require the expression of C3 to elicit a fully activated Th1 response. In addition, it appears from our measurements of IL-10 and foxp3, that the regulatory T cell driving capacity of DCs was also dependent on C3.

To verify the role of C3 suggested in the studies with C3 knockout DC, we performed a gene-silencing experiment using WT DCs. The finding of reduced T cell stimulation with C3-inhibited DCs establishes a causal relationship between C3 expression and the T cell stimulatory capacity of DCs. However, in addition to deficient C3 production, the DCs derived from the knockout mice also exhibited reduced cell surface expression of MHC class II and B7.2 molecules, suggesting that the reduced capacity of these cells to elicit a T cell response may have been due to lack of Ag (allo-MHC) and costimulatory molecules, in addition to lack of C3. However, there was no apparent defect of gene expression for MHC class II and B7.2, indicating that the lack of cell surface immunoregulatory molecules in the deficient DCs was not the result of associated gene defects, but may have been secondary to C3 deficiency. Taken together, our data with C3 knockout DCs and C3-inhibited DCs suggest that C3 is the primary defect underlying the weakened capacity of these cells for T cell stimulation.

The property of DCs to synthesize C3 is compatible with the known physiological and pathological functions of DCs in vivo. In the normal steady state (absence of inflammation or "danger" signal), DCs appear to produce only a small amount of C3, which is perhaps consistent with DCs having a limited ability to stimulate an immune response. Low level production of C3 may also benefit the elimination of abnormal tissue or cells, such as damaged, apoptotic, and mutant cells from the host, by the innate immune system (1). In contrast, in some pathological conditions, DC synthesis of C3 may be up-regulated by microbial factors such as LPS and by nonspecific inflammatory stimuli such cytokines, ischemia/reperfusion injury, and surgery. These nonspecific inflammatory stimuli have been shown to up-regulate C3 synthesis in vitro and in vivo (19, 36, 37, 38). Given the observations that DC synthesis of C3 is an important characteristic of DC activation, up-regulation of DC synthesis of C3 during inflammation and infection could enhance the DC’s Ag-presenting capacity.

The results presented here have important implications for organ transplantation. Alloantigen is a unique Ag that is synthesized by donor APCs and includes alloantigenic MHC molecules and MHC/peptide complexes (39). The principal effector mechanism underlying acute organ transplant rejection is the vigorous adaptive immune response mounted by recipient T cells against donor alloantigen (25, 40). CD4+ T cells play a central role in mediating graft rejection by producing cytokines that direct the proliferation and differentiation of effector cells, such as T cells and macrophages. It has been proposed that a Th1-driven response mediates the destruction of the graft, while a Th2-driven response may favor the induction of tolerance to the graft (41, 42). More recently, a study of mouse skin allograft rejection found that 90% of T cells responded to directly presented donor MHC peptide, whereas <10% of T cells recognized allopeptide indirectly presented by recipient APCs (43). Thus, donor APCs appear to play an important role in acute rejection. DCs are the main APCs involved in initiation of the T cell response that mediates acute rejection (44). However, DCs also play a critical role in induction/maintenance of peripheral T cell tolerance, possible through the Th2-driven response and the development of regulatory T cells. In this study, we showed that all three of these DC properties–CD4+ T cell stimulation, Th2 polarization, and regulatory T cell-driving capacity, are modulated by donor-derived C3. Additionally, we demonstrated the functional consequences of defective T cell priming with C3–/– DCs, in terms of the tempo of skin allograft rejection. Together these findings provide compelling evidence that the C3 status of DCs can regulate the alloimmune response. This offers an explanation, at least in part, for our earlier observation that C3–/– renal allografts result in much weaker graft rejection (24).

The mechanism by which the C3 status of donor DCs affects DC function in alloreactive T cell responses needs further elucidation. However, one of the possible explanations is that, in the presence of other relevant components and factors, locally produced C3 could lead to complement activation and generate complement effector molecules. Released soluble effectors such as C3a, binding to the G-protein-coupled receptor on DCs, could lead to enhanced DC activation and migration (45). A sublethal dose of C5b-9 deposited on the DC surface may also activate DCs causing cytokine release. Such an effect has been shown on macrophages (46). In addition, C3 could regulate DC function through an intracellular mechanism. Previous studies using B cells as APCs, have revealed that Ag coupled covalently to C3b is protected from excessive proteolytic degradation in the endosomal/lysosomal compartment of the MHC class II pathway, suggesting that activated C3 fragment functions as a "chaperone" in the MHC class II pathway of APCs, which is essential for maintaining the normal function of APCs (47, 48). Our data showing that the impact of DC synthesis of C3 was mainly on CD4+ T cells, and the finding of reduced MHC class II expression on C3–/– DCs, are consistent with an effect of C3 on the MHC class II pathway of Ag presentation. These findings also agree with the notion that C3 produced by donor DCs could prevent allogeneic MHC molecules from excessive degradation in intracellular organelles, thus enhancing allo-MHC molecule stability and consequently promoting DC activation.

In conclusion, our data provide evidence of a new and fundamental characteristic of DCs that appears to influence the development of the Th1 response and emergence of the regulatory T cell phenotype. Lack of C3 defines a shift in the immunoregulatory function of DCs, with a swing toward a Th2/regulatory phenotype and a delay of graft rejection. These findings provide further insight into the mechanism of T cell hyporesponsiveness in C3–/– mice, and offer an explanation, at least in part, for the amelioration of graft rejection with C3–/– donor kidney. Finally, our findings may provide an additional basis for investigating possible therapeutic uses of DCs in organ transplantation and other immunological conditions.


    Acknowledgments
 
We are grateful to Professor M. Carroll for providing the C3 knockout mice. We thank Drs. Stipo Jurcevic and Roseanna Hargreaves for helpful scientific discussions.


    Disclosures
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The authors have no financial conflict of interest.


    Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the Wellcome Trust, Medical Research Council of U.K., and the Guy’s and St. Thomas’ Kidney Patients’ Association, U.K. Back

2 Address correspondence and reprint requests to Dr. Wuding Zhou, Department of Nephrology and Transplantation, 5th Floor, Thomas Guy House, Guy’s Hospital, London SE1 9RT, U.K. E-mail address: wuding.zhou{at}kcl.ac.uk Back

3 Abbreviations used in this paper: DC, dendritic cell; WT, wild type; RT-qPCR, RT-quantitative PCR; Ct, cycle threshold; siRNA, small interfering RNA. Back

Received for publication July 26, 2005. Accepted for publication December 28, 2005.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Janeway, C. A., Jr, R. Medzhitov. 2002. Innate immune recognition. Annu. Rev. Immunol. 20: 197-216. [Medline]
  2. Walport, M. J.. 2001. Complement: first of two parts. N. Engl. J. Med. 344: 1058-1066. [Free Full Text]
  3. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767-811. [Medline]
  4. Carroll, M. C.. 2004. The complement system in regulation of adaptive immunity. Nat. Immunol. 5: 981-986. [Medline]
  5. de Jong, E. C., H. H. Smits, M. L. Kapsenberg. 2005. Dendritic cell-mediated T cell polarization. Springer Semin. Immunopathol. 26: 289-307. [Medline]
  6. Steinman, R. M.. 2003. Some interfaces of dendritic cell biology. APMIS 111: 675-697. [Medline]
  7. Sparri, R., C. Reis e Sousa. 2005. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol. 6: 163-170. [Medline]
  8. Reis e Sousa, C.. 2004. Activation of dendritic cells: translating innate into adaptive immunity. Curr. Opin. Immunol. 16: 21-25. [Medline]
  9. Rock, K. L., A. Hearn, C. J. Chen, Y. Shi. 2005. Natural endogenous adjuvants. Springer Semin. Immunopathol. 26: 231-246. [Medline]
  10. Fischer, M. B., M. Ma, S. Goerg, X. Zhou, J. Xia, O. Finco, S. Han, G. Kelsoe, R. G. Howard, T. L. Rothstein, et al 1996. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J. Immunol. 157: 549-556. [Abstract]
  11. Wessels, M. R., P. Butko, M. Ma, H. B. Warren, A. L. Lage, M. C. Carroll. 1995. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA 92: 11490-11494. [Abstract/Free Full Text]
  12. Ochsenbein, A. F., D. D. Pinschewer, B. Odermatt, M. C. Carroll, H. Hengartner, R. M. Zinkernagel. 1999. Protective T cell-independent antiviral antibody responses are dependent on complement. J. Exp. Med. 190: 1165-1174. [Abstract/Free Full Text]
  13. Dempsey, P. W., M. E. Allison, S. Akkaraju, C. C. Goodnow, D. T. Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271: 348-350. [Abstract]
  14. Kopf, M., B. Abel, A. Gallimore, M. Carroll, M. F. Bachmann. 2002. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat. Med. 8: 373-378. [Medline]
  15. Suresh, M., H. Molina, M. S. Salvato, D. Mastellos, J. D. Lambris, M. Sandor. 2003. Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J. Immunol. 170: 788-794. [Abstract/Free Full Text]
  16. Kaya, Z., M. Afanasyeva, Y. Wang, K. M. Dohmen, J. Schlichting, T. Tretter, D. Fairweather, V. M. Holers, N. R. Rose. 2001. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat. Immunol. 2: 739-745. [Medline]
  17. Marsh, J. E., C. K. Farmer, S. Jurcevic, Y. Wang, M. C. Carroll, S. H. Sacks. 2001. The allogeneic T and B cell response is strongly dependent on complement components C3 and C4. Transplantation 72: 1310-1318. [Medline]
  18. Alper, C. A., A. M. Johnson, A. G. Birtch, F. D. Moore. 1969. Human C’3: evidence for the liver as the primary site of synthesis. Science 163: 286-288. [Abstract/Free Full Text]
  19. Colten, H. R., R. C. Strunk, D. H. Perlmutter, F. S. Cole. 1986. Regulation of complement protein biosynthesis in mononuclear phagocytes. Ciba Found. Symp. 118: 141-154. [Medline]
  20. Botto, M., D. Lissandrini, C. Sorio, M. J. Walport. 1992. Biosynthesis and secretion of complement component (C3) by activated human polymorphonuclear leukocytes. J. Immunol. 149: 1348-1355. [Abstract]
  21. Brooimans, R. A., A. P. Stegmann, W. T. van Dorp, A. A. van der Ark, F. J. van der Woude, L. A. van Es, M. R. Daha. 1991. Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. J. Clin. Invest. 88: 379-384. [Medline]
  22. Sacks, S. H., W. Zhou, A. Pani, R. D. Campbell, J. Martin. 1993. Complement C3 gene expression and regulation in human glomerular epithelial cells. Immunology 79: 348-354. [Medline]
  23. Fischer, M. B., M. Ma, N. C. Hsu, M. C. Carroll. 1998. Local synthesis of C3 within the splenic lymphoid compartment can reconstitute the impaired immune response in C3-deficient mice. J. Immunol. 160: 2619-2625. [Abstract/Free Full Text]
  24. Pratt, J. R., S. A. Basheer, S. H. Sacks. 2002. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat. Med. 8: 582-587. [Medline]
  25. Lechler, R. I., J. R. Batchelor. 1982. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J. Exp. Med. 155: 31-41. [Abstract/Free Full Text]
  26. Golshayan, D., R. Lechler. 2004. Commentary: priming of alloreactive T cells–where does it happen?. Eur. J. Immunol. 34: 3301-3304. [Medline]
  27. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176: 1693-1702. [Abstract/Free Full Text]
  28. Van den Berg, C. W., H. Van Dijk, P. J. Capel. 1989. Rapid isolation and characterization of native mouse complement components C3 and C5. J. Immunol. Methods 122: 73-78. [Medline]
  29. Pfaffl, M. W., G. W. Horgan, L. Dempfle. 2002. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30: -e36[Abstract/Free Full Text]
  30. Krupnick, A. S., A. E. Gelman, W. Barchet, S. Richardson, F. H. Kreisel, L. A. Turka, M. Colonna, G. A. Patterson, D. Kreisel. 2005. Cutting edge: murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J. Immunol. 175: 6265-6270. [Abstract/Free Full Text]
  31. Levings, M. K., R. Sangregorio, F. Galbiati, S. Squadrone, M. R. de Waal, M. G. Roncarolo. 2001. IFN-{alpha} and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. 166: 5530-5539. [Abstract/Free Full Text]
  32. Kretschmer, K., I. Apostolou, D. Hawiger, K. Khazaie, M. C. Nussenzweig, H. von Boehmer. 2005. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6: 1219-1227. [Medline]
  33. Yamazaki, S., T. Iyoda, K. Tarbell, K. Olson, K. Velinzon, K. Inaba, R. M. Steinman. 2003. Direct expansion of functional CD25+CD4+ regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198: 235-247. [Abstract/Free Full Text]
  34. Fontenot, J. D., M. A. Gavin, A. Y. Rudensky. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4: 330-336. [Medline]
  35. Oh, K. H., J. Y. Kim, D. Kim, E. M. Lee, H. Y. Oh, J. S. Seo, J. S. Han, S. Kim, J. S. Lee, C. Ahn. 2004. Targeted gene disruption of the heat shock protein 72 gene (hsp70.1) in the donor tissue is associated with a prolonged rejection-free survival in the murine skin allograft model. Transplant Immunol. 13: 273-281. [Medline]
  36. Andrews, P. A., W. Zhou, S. H. Sacks. 1995. Tissue synthesis of complement as an immune regulator. Mol. Med. Today 1: 202-207. [Medline]
  37. Zhou, W., J. E. Marsh, S. H. Sacks. 2001. Intrarenal synthesis of complement. Kidney Int. 59: 1227-1235. [Medline]
  38. Sacks, S. H., W. Zhou. 2003. Locally produced complement and its role in renal allograft rejection. Am. J. Transplant. 3: 927-932. [Medline]
  39. Lechler, R. I., G. Lombardi, J. R. Batchelor, N. Reinsmoen, F. H. Bach. 1990. The molecular basis of alloreactivity. Immunol. Today 11: 83-88. [Medline]
  40. Golshayan, D., R. Lechler. 2004. Commentary: priming of alloreactive T cells—where does it happen?. Eur. J. Immunol. 34: 3301-3304. [Medline]
  41. Dallman, M. J.. 1995. Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Curr. Opin. Immunol. 7: 632-638. [Medline]
  42. Strom, T. B., P. Roy-Chaudhury, R. Manfro, X. X. Zheng, P. W. Nickerson, K. Wood, A. Bushell. 1996. The Th1/Th2 paradigm and the allograft response. Curr. Opin. Immunol. 8: 688-693. [Medline]
  43. Benichou, G., A. Valujskikh, P. S. Heeger. 1999. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J. Immunol. 162: 352-358. [Abstract/Free Full Text]
  44. Lechler, R., W. F. Ng, R. M. Steinman. 2001. Dendritic cells in transplantation–friend or foe?. Immunity 14: 357-368. [Medline]
  45. Kirchhoff, K., O. Weinmann, J. Zwirner, G. Begemann, O. Gatze, A. Kapp, T. Werfel. 2001. Detection of anaphylatoxin receptors on CD83+ dendritic cells derived from human skin. Immunology 103: 210-217. [Medline]
  46. Imagawa, D. K., N. E. Osifchin, L. E. Ramm, P. G. Koga, C. H. Hammer, H. S. Shin, M. M. Mayer. 1986. Release of arachidonic acid and formation of oxygenated derivatives after complement attack on macrophages: role of channel formation. J. Immunol. 136: 4637-4643. [Abstract]
  47. Jacquier-Sarlin, M. R., F. M. Gabert, M. B. Villiers, M. G. Colomb. 1995. Modulation of antigen processing and presentation by covalently linked complement C3b fragment. Immunology 84: 164-170. [Medline]
  48. Serra, V. A., F. Cretin, E. Pepin, F. M. Gabert, P. N. Marche. 1997. Complement C3b fragment covalently linked to tetanus toxin increases lysosomal sodium dodecyl sulfate-stable HLA-DR dimer production. Eur. J. Immunol. 27: 2673-2679. [Medline]



This article has been cited by other articles:


Home page
J. Immunol.Home page
Q. Peng, K. Li, N. Wang, Q. Li, E. Asgari, B. Lu, T. M. Woodruff, S. H. Sacks, and W. Zhou
Dendritic Cell Function in Allostimulation Is Modulated by C5aR Signaling
J. Immunol., November 15, 2009; 183(10): 6058 - 6068.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Nakayama, S.-I. Kim, E. H. Kim, J. D. Lambris, M. Sandor, and M. Suresh
C3 Promotes Expansion of CD8+ and CD4+ T Cells in a Listeria monocytogenes Infection
J. Immunol., September 1, 2009; 183(5): 2921 - 2931.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Fang, X. Zhang, T. Miwa, and W.-C. Song
Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production
Blood, July 30, 2009; 114(5): 1005 - 1015.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
C. Villiers, M. Chevallet, H. Diemer, R. Couderc, H. Freitas, A. Van Dorsselaer, P. N. Marche, and T. Rabilloud
From Secretome Analysis to Immunology: CHITOSAN INDUCES MAJOR ALTERATIONS IN THE ACTIVATION OF DENDRITIC CELLS VIA A TLR4-DEPENDENT MECHANISM
Mol. Cell. Proteomics, June 1, 2009; 8(6): 1252 - 1264.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Baruah, I. E. Dumitriu, T. H. Malik, H. T. Cook, J. Dyson, D. Scott, E. Simpson, and M. Botto
C1q enhances IFN-{gamma} production by antigen-specific T cells via the CD40 costimulatory pathway on dendritic cells
Blood, April 9, 2009; 113(15): 3485 - 3493.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
K. L. Mershon, A. Vasuthasawat, G. W. Lawson, S. L. Morrison, and D. O. Beenhouwer
Role of Complement in Protection against Cryptococcus gattii Infection
Infect. Immun., March 1, 2009; 77(3): 1061 - 1070.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Li, K. J. Anderson, Q. Peng, A. Noble, B. Lu, A. P. Kelly, N. Wang, S. H. Sacks, and W. Zhou
Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation
Blood, December 15, 2008; 112(13): 5084 - 5094.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. Pavlov, H. Raedler, S. Yuan, S. Leisman, W.-h. Kwan, P. N. Lalli, M. E. Medof, and P. S. Heeger
Donor Deficiency of Decay-Accelerating Factor Accelerates Murine T Cell-Mediated Cardiac Allograft Rejection
J. Immunol., October 1, 2008; 181(7): 4580 - 4589.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Ghannam, M. Pernollet, J.-L. Fauquert, N. Monnier, D. Ponard, M.-B. Villiers, J. Peguet-Navarro, A. Tridon, J. Lunardi, D. Gerlier, et al.
Human C3 Deficiency Associated with Impairments in Dendritic Cell Differentiation, Memory B Cells, and Regulatory T Cells
J. Immunol., October 1, 2008; 181(7): 5158 - 5166.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. Sacks and W. Zhou
New Boundaries for Complement in Renal Disease
J. Am. Soc. Nephrol., October 1, 2008; 19(10): 1865 - 1869.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Spirig, C. van Kooten, C. Obregon, L. Nicod, M. Daha, and R. Rieben
The Complement Inhibitor Low Molecular Weight Dextran Sulfate Prevents TLR4-Induced Phenotypic and Functional Maturation of Human Dendritic Cells
J. Immunol., July 15, 2008; 181(2): 878 - 890.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Q. Peng, K. Li, K. Anderson, C. A. Farrar, B. Lu, R. A. G. Smith, S. H. Sacks, and W. Zhou
Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction
Blood, February 15, 2008; 111(4): 2452 - 2461.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. N. Lalli, M. G. Strainic, F. Lin, M. E. Medof, and P. S. Heeger
Decay Accelerating Factor Can Control T Cell Differentiation into IFN-{gamma}-Producing Effector Cells via Regulating Local C5a-Induced IL-12 Production
J. Immunol., November 1, 2007; 179(9): 5793 - 5802.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peng, Q.
Right arrow Articles by Zhou, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peng, Q.
Right arrow Articles by Zhou, W.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS